reference/3904148

http://rdf.ncbi.nlm.nih.gov/pubchem/reference/3904148

Outgoing Links

Predicate	Object
contentType	Journal Article\|Randomized Controlled Trial\|Research Support, N.I.H., Extramural
endingPage	435
issn	1461-7285 0269-8811
issueIdentifier	5
pageRange	428-435
publicationName	Journal of psychopharmacology (Oxford, England)
startingPage	428
hasFundingAgency	http://rdf.ncbi.nlm.nih.gov/pubchem/organization/MD5_cd23225bb8277d80089ba14432de98d3
isSupportedBy	http://rdf.ncbi.nlm.nih.gov/pubchem/grant/MD5_e0a34554cb1437e81cb4d8f8d7953dac
bibliographicCitation	Girgis RR, Van Snellenberg JX, Glass A, Kegeles LS, Thompson JL, Wall M, Cho RY, Carter CS, Slifstein M, Abi-Dargham A, Lieberman JA. A proof-of-concept, randomized controlled trial of DAR-0100A, a dopamine-1 receptor agonist, for cognitive enhancement in schizophrenia. J Psychopharmacol. 2016 May;30(5):428–35. doi: 10.1177/0269881116636120. PMID: 26966119.
creator	http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_e040218ba0905502479edb52185cfc8a http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_367f11836223cd6bbf2176579f68c6c4 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_9cff374cbec7285174daa3d77f0675b3 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_27e530dde53684f175737edb16fd6716 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_65cd0d1535e081a6eb99d36439478663 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_4c69ea3b15592f10a7a1da7f285c2bd2 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_904ead123bf4c689399c937414a7b66b http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_3e666d162a2052a8a44eebd894d7c4c7 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_fa07095fc524040312bf2c42c464ff8b http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_f5443a47a7d62d80b4e84d85b92ad5bc http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_2a495f6fbce5274d03599191837e7726
date	2016-03-10^^<http://www.w3.org/2001/XMLSchema#date>
identifier	https://doi.org/10.1177/0269881116636120 https://pubmed.ncbi.nlm.nih.gov/26966119
isPartOf	https://portal.issn.org/resource/ISSN/0269-8811 https://portal.issn.org/resource/ISSN/1461-7285 http://rdf.ncbi.nlm.nih.gov/pubchem/journal/20554
language	English
source	https://pubmed.ncbi.nlm.nih.gov/ https://www.crossref.org/
title	A proof-of-concept, randomized controlled trial of DAR-0100A, a dopamine-1 receptor agonist, for cognitive enhancement in schizophrenia
discusses	http://id.nlm.nih.gov/mesh/M0027733 http://id.nlm.nih.gov/mesh/M0170608 http://id.nlm.nih.gov/mesh/M0016489 http://id.nlm.nih.gov/mesh/M0021770 http://id.nlm.nih.gov/mesh/M0006756 http://id.nlm.nih.gov/mesh/M0028009 http://id.nlm.nih.gov/mesh/M0026472
hasPrimarySubjectTerm	http://id.nlm.nih.gov/mesh/D018491Q000627 http://id.nlm.nih.gov/mesh/D004298Q000378 http://id.nlm.nih.gov/mesh/D018697Q000627 http://id.nlm.nih.gov/mesh/D012559Q000188 http://id.nlm.nih.gov/mesh/D014150Q000627 http://id.nlm.nih.gov/mesh/D010617Q000627 http://id.nlm.nih.gov/mesh/D017447Q000819
hasSubjectTerm	http://id.nlm.nih.gov/mesh/D011569 http://id.nlm.nih.gov/mesh/D002540Q000378 http://id.nlm.nih.gov/mesh/D006801 http://id.nlm.nih.gov/mesh/D000328 http://id.nlm.nih.gov/mesh/D005260 http://id.nlm.nih.gov/mesh/D003071Q000187 http://id.nlm.nih.gov/mesh/D003072Q000188 http://id.nlm.nih.gov/mesh/D001288Q000187 http://id.nlm.nih.gov/mesh/D012559Q000378 http://id.nlm.nih.gov/mesh/D009483 http://id.nlm.nih.gov/mesh/D004311 http://id.nlm.nih.gov/mesh/D002540Q000187 http://id.nlm.nih.gov/mesh/D003072Q000378 http://id.nlm.nih.gov/mesh/D008297 http://id.nlm.nih.gov/mesh/D008570Q000187
discussesAsDerivedByTextMining	http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5234 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID9168 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID7296 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID681 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID6603820

Showing number of triples: 1 to 66 of 66.